and only limited evidence on harms (including cost).
Dr Braillon is also correct that we had no intervention in the control arm. An intervention like health education in this arm would potentially leave open the question of effectiveness. If there were no difference in colorectal cancer mortality between the arms, one would not know whether this was due to similar effectiveness of the interventions or no effect of FOBT (and education). A design which cannot answer the question would be unethical.
We do not think the Helsinki declaration point 32 on inferior treatment applies here. FOBT is generally available and in routine use but promoting indiscriminate use may lead to problems. Limited resources and variation in health-care policies mean that trial results may not always be reproducible, and there are always potential harms from screening. Screening may, for example, promote unfavourable lifestyle changes and these could have a bigger harmful health effect than the small benefit (lower mortality from colorectal cancer) from screening. In several trials the overall mortality was higher in the screening arm than the control arm. No-screening is therefore not an inferior intervention.
To our knowledge there are no organized screening programmes in the US for any cancer site. In much of Northern Europe, by contrast, the public sector provides health care and cancer screening programmes are national and cost-free for the attendee, and based on invitation and particularistic evidence on mortality. The threshold to launch such a programme is higher than the threshold to give a recommendation on indiscriminate screening. This difference explains some, but not all, of the ethical issues.
Comparing Europe with the US is not valid, and raises ethical problems. A public health policy should maintain equity of access, cover the population with more than a theoretical risk (age 49 is far too low for CRC screening), and should be evidence-based. Virtual colonoscopy (or any colonoscopy) has not been studied and the information on effectiveness and harms (like overdiagnosis of preinvasive lesions) is lacking.
The design for colorectal cancer screening programme in Finland with individual randomization was based on several factors: a new programme could not be immediately launched with 100% coverage (not logistically possible, lack of colonoscopy resources etc.). Random allocation of screenees and use of all the available resources maintains equity in the society because everybody has the same a priori chance to be screened, and if the programme is not effective or turns out to be harmful, the chance of not being screened is the same for everyone.
We designed the programme, given the available resources, to provide the correct answers to relevant questions as quickly as possible. The programme will show whether screening works and whether it should be continued. It can be modified or stopped if it is not effective or if it is harmful. The general evidence on the expected effect indicates a relatively small reduction in mortality. Most programmes cannot demonstrate such a marginal effect if not randomized at the implementation phase. This is also true in France, where it will probably never be possible to know whether to continue with screening, to modify the programme, or to stop screening.
We therefore believe that our programme maximizes the benefits and minimizes the harms and costs, can be properly evaluated, and is ethically justified.
Nea Malila* † , Tiina Palva ‡ , Outi Malminiemi § , Hannu Paimela**, Ahti Anttila*, Timo Hakulinen*, demonstrates clearly the anguished responses of women to the predicament of screen-detected ductal carcinoma in situ (DCIS). 1 The findings confirm what has been known since the outset of the screening programme: a diagnosis of DCIS distresses women. 2, 3 However, we disagree with the conclusion that 'Better information about the uncertainties and the rationale for mastectomy as a treatment may help women to make better informed choices and feel more comfortable about their decisions' as this refers to information and decisions after screening and assumes that the rationale may not be questioned, still less rationally declined.
The results showed four key themesaround the women's understanding of DCIS and its treatment, but also their understanding of routine breast screening and their individual risk of developing breast cancer. We suggest that this is the nub of the difficulties.
When information about the uncertainties and rationale for treating DCIS is given at this late point women are likely to realize that in attending screening they took a gamble whose implications had not been explained and to feel that being 'railroaded' into serious surgery on insufficient evidence is at best questionable, at worst unwarranted. Rather than therapy, which they were led to expect, it is a pre-emptive strike. As difficult as 'Sophie's choice'. Hence the familiar distress.
In light of recent screening mammography research 4 -6 it would not be irrational to decline screening to avoid this predicament. Nor would it be irrational to decline treatment when mammograms and further tests have provided no additional information over and above what every woman already knows: that she may or may not, at some unpredictable time, develop life-threatening breast cancer. For those who go on to develop symptoms, increasingly successful treatments can be offered without the traumatic uncertainty. This evaluation cannot be made for an individual woman by doctors since the balancing of quantity of life over the obvious threats to quality in the face of unquantifiable risk depend on personal values which professionals cannot second guess or pre-empt as is current practice.
All practitioners in this field must have faced dozens, perhaps hundreds, of women in this predicament. Their profound suffering is obvious, indeed expected, and entirely avoidable. Yet screeners continue to give inadequate preparatory information, 1, 7, 8 Pryke et al. confirm many of the points made in our previous work on DCIS. Our recent paper explored women's concerns about having a mastectomy for screen-detected DCIS 1 , including their information needs when making treatment decisions, particularly about mastectomy. As they point out, it is known that a DCIS diagnosis, understandably, causes much distress. 2, 3 Less has been written, however, on what kind of information might be helpful to women. 4 -6 We believe that the information given to women before screening and when making treatment decisions is crucial.
In our 2006 paper 7 based on in-depth interviews with women diagnosed with screen-detected DCIS, we highlighted that women know little about DCIS before being diagnosed with it and would have liked more comprehensive information about routine breast screening, including DCIS as a possible outcome, in order to make properly informed choices about whether to attend for routine screening. Specifically: † None of the women interviewed had heard about DCIS before their own diagnosis. † Some women were shocked by the large numbers of women diagnosed with DCIS annually, and questioned why the NHS breast screening leaflet they had received made no mention of it. † Women wanted more information about mammographic screening before attending -information about the benefits, risks and limitations of breast screening, and all the possible outcomes, including the possibility of a DCIS diagnosis.
Many of the women we interviewed learnt about DCIS and more about mammographic screening after their diagnosis, and then felt able to make an informed choice about whether to have mammograms in future. Knowing more about the risks and benefits of screening mammography, about DCIS, its incidence and complexity, a few women deferred appointments for mammograms or resolved not to have mammograms again. Having learned how poorly understood DCIS was, some of these women regretted ever having gone for screening and doubted whether it should be offered for a condition that doctors do not know how to treat and which could remain harmless for many years. These women said they did not want to be faced with the uncertainties associated with DCIS again and questioned whether DCIS was 'worth knowing about' when it could remain harmless for many years. A few women felt that, if they were to be diagnosed with DCIS again, they might defer surgery or refuse to have it at all.
Other women, including those who had not wanted more information or had believed they had invasive breast cancer, chose to continue having mammograms. Some said they found follow-up appointments reassuring because potential breast problems would be detected early. Several were glad they had been screened, believing that it had prevented them from developing invasive cancer and saved their lives, and therefore encouraged other women to attend.
We have highlighted these very important issues in our papers and also on our website, which focuses specifically on women's experiences of DCIS, showing extracts from women's interviews in audio, video and written formats: http://www. healthtalkonline.org/Cancer/ductal_ carcinoma_in_situ.
We agree that there is now sufficient qualitative research evidence about the distress caused by a DCIS diagnosis, and hope that clinicians will recommend the Healthtalkonline site to women before screening and when faced with treatment dilemmas, so that they can make their decisions in the light of other women's experiences.
Although the NHS breast screening leaflet has been modified recently, it does not mention DCIS until page 10
